comparemela.com

Latest Breaking News On - Sandi greenwood - Page 13 : comparemela.com

OncoArendi Therapeutics Appoints Samson Fung, M D as Chief Medical Officer

/PRNewswire/ OncoArendi Therapeutics S.A. ("OncoArendi"; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal.

Eleanor perkinFrazer hallMarcin szumowskiSamson fungMagdalena lickaSandi greenwoodUniversity of freiburgWarsaw stock exchangeInternational institute of molecularHead of clinical developmentNovo nordiskChief medicalClinical developmentDavid dibleInternational instituteCell biology

OncoArendi Therapeutics Appoints Samson Fung, M D as Chief Medical Officer

Dr. Fung to Lead Global Clinical Development, Translational Science and Regulatory Strategies WARSAW, Poland, Jan. 27, 2022 /PRNewswire/ OncoArendi Therapeutics S.A. ("OncoArendi"; WSE:

Eleanor perkinFrazer hallSamson fungMarcin szumowskiMagdalena lickaSandi greenwoodUniversity of freiburgWarsaw stock exchangeInternational institute of molecularHead of clinical developmentFung to lead global clinical developmentNovo nordiskLead global clinical developmentTranslational scienceChief medicalClinical development

Pneumagen Raises £3 8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)

/PRNewswire/ Pneumagen, a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral.

United kingdomCity ofCathal frielFrazer hallPneumagen neumifilThairm bio mark bamforthThairm bioDouglas thomsonSandi greenwoodUniversity of st andrewsVenn life sciencesOpen orphanMark bamforthGrowth investmentsScottish enterpriseHelping pneumagen

Pneumagen Raises £3 8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)

/PRNewswire/ Pneumagen, a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral.

United kingdomCity ofCathal frielFrazer hallPneumagen neumifilThairm bio mark bamforthThairm bioDouglas thomsonSandi greenwoodUniversity of st andrewsVenn life sciencesOpen orphanMark bamforthGrowth investmentsScottish enterpriseHelping pneumagen

Pneumagen Raises £3 8 million to Advance the Phase II Clinical Development of Neumifil, a Pan-antiviral, Intranasal Drug for the Prophylaxis and Treatment of Viral Respiratory Tract Infections (RTIs)

ST ANDREWS, Scotland, Jan. 19, 2022 /PRNewswire/ Pneumagen, a clinical stage biotech company developing Neumifil, a pan-antiviral, intranasal drug for the prophylaxis and treatment of viral

United kingdomCity ofCathal frielFrazer hallPrnewswire pneumagenThairm bioThairm bio mark bamforthPneumagen neumifilDouglas thomsonSandi greenwoodUniversity of st andrewsVenn life sciencesOpen orphanMark bamforthGrowth investmentsScottish enterprise

vimarsana © 2020. All Rights Reserved.